Abstract Library

#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study

Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pavel M, Wiedenmann B, Seufferlein T, Freiman J, Law L,

Keywords: carcinoid syndrome, telotristat etiprate ,

#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study

Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulke M, O'Dorisio T, Phan A, Bergsland E, Freiman J,

Keywords: carcinoid syndrome, telotristat etiprate,

#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome

Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Brown P

Authors: Brown P, Jackson J, Frazier K, Turnage A, Clark E,

Keywords: carcinoid syndrome, TPH inhibitor, 5-HT, tryptophan hydroxylase, clinical trial, serotonin synthesis, serotonin synthesis inhibitor, LX1032, LX1031, Lexicon, IBS, irritable bowel syndrome, SSI,